Ignite Creation Date:
2024-05-06 @ 2:13 PM
Last Modification Date:
2024-10-26 @ 1:27 PM
Study NCT ID:
NCT04250389
Status:
COMPLETED
Last Update Posted:
2020-01-31
First Post:
2020-01-29
Brief Title:
Microcirculatory Effects of Methylene Blue
Sponsor:
Hospices Civils de Lyon
Organization:
Hospices Civils de Lyon
Study Overview
Official Title:
Microcirculatory Effects of Methylene Blue in Vasoplegic Shock After Cardiopulmonary Bypass a Pilot Study
Status:
COMPLETED
Status Verified Date:
2020-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MAGIC BLUE
Brief Summary:
International guidelines recommend Methylene Blue MB as a second-line drug in the treatment of norepinephrine refractory vasoplegic shock VS after Cardiopulmonary Bypass CPB Macrocirculatory effects of MB in this setting are now well established but microcirculatory effects of MB remain unknown
The purpose of this study is to assess the micro vascular effects of a single administration of methylene blue 15 mgkg over 30 minutes for norepinephrine-refractory VS post CPB
Microcirculatory effect will be monitored before and one hour after MB infusion through cutaneous refill time video microscopy measurements of the sublingual microcirculation and tissue oxygen saturation combined with vascular occlusion test VOT
The purpose of this study is to assess the micro vascular effects of a single administration of methylene blue 15 mgkg over 30 minutes for norepinephrine-refractory VS post CPB
Microcirculatory effect will be monitored before and one hour after MB infusion through cutaneous refill time video microscopy measurements of the sublingual microcirculation and tissue oxygen saturation combined with vascular occlusion test VOT
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None